Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No HPO annotations are available for this condition.
The clinical findings of spinocerebellar ataxia type 10 (SCA10) are relatively homogeneous. Ataxia causes progressive disability, and seizures may become life threatening if status epilepticus emerges. Reported age of onset ranges from 12 to 83 years [, , , , ]. To date, more than 300 individuals have been identified with SCA10. The following description of the phenotypic features associated with this condition is based on these reports. Ataxia. The central feature of the phenotype is slowly progressive cerebellar ataxia that usually starts as poor balance and unsteady gait. The gait ataxia gradually worsens, leading to an increasing number of falls and necessitating use of a cane, walker, and eventually wheelchair.
Spinocerebellar ataxia type 10 (SCA10) should be suspected in individuals with the following findings:
Slowly progressive cerebellar ataxia starting as poor balance and unsteady gait
Scanning dysarthria, dysphagia, and upper-limb ataxia following the gait ataxia
Family history consistent with autosomal dominant inheritance and Native American or East Asian ancestry
No approved treatments are currently available for autosomal dominant cerebellar ataxia type IV. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with spinocerebellar ataxia type 10 (SCA10), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with SCA10
Table 5.
Recommended Surveillance for Individuals with SCA10
System/Concern | Evaluation | Frequency
| Clinical evaluation w/neurologist | Every 4-6 mos to identify early signs of potential complications to adjust anticonvulsant treatments
Video esophagrams can identify consistency of food least likely to trigger aspiration. | As needed in individuals w/dysphagia
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
35 publications have been identified in PubMed for autosomal dominant cerebellar ataxia type IV. Research spans Case Report / Case Series (30%), Basic Science / Preclinical (30%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 10 | 30% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 9:05 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "Spinocerebellar Ataxia Type 10"
Generalized motor seizures and/or complex partial seizures
Note: Ataxia and its impact on quality of life is mild compared to SCA3 . Other suggestive findings:
Source: GeneReviews — "Spinocerebellar Ataxia Type 10"
Significant overlap exists in the clinical presentation of the SCAs (see Hereditary Ataxia Overview). All are characterized by ataxia, and some by other neurologic signs. Clinical presentation may vary even among affected members of the same family. SCA type cannot generally be determined by clinical or neuroimaging studies of single individuals. Although the combination of "pure" cerebellar ataxia (lacking other motor or cranial nerve involvement) and seizures is typical for SCA10 and has seldom been seen in other autosomal dominant cerebellar ataxias, it is possible that in some families, SCA10 could be a pure cerebellar ataxia without seizures. See for notable clinical features of selected hereditary disorders in the differential diagnosis of SCA10. Table 2. Hereditary Ataxia Disorders of Interest in the Differential Diagnosis of Spinocerebellar Ataxia Type 10
Gene | Disorder | MOI | Clinical Features |
|---|---|---|---|
DRPLA | AD | Seizures; Conspicuous neurologic signs (e.g., extrapyramidal signs) not seen in SCA10 ATXN1 | — |
SCA1 | AD | Pyramidal signs are more robust than in SCA10. ATXN2 | — |
SCA2 | AD | Slow saccadic eye movements (not seen in SCA10) ATXN3 | — |
SCA3 | AD | More extensive extrapyramidal signs involvement of lower motor neurons than in SCA10 ATXN7 | — |
SCA7 | AD | Retinopathy w/macular degeneration (not seen in SCA10) | — |
FMR1 | FXTAS (See FMR1-Related Disorders.) | XL | Onset of ataxia is later (age 50 yrs) than that assoc w/SCA10 full-penetrance alleles, but may be earlier than that assoc w/SCA10 reduced-penetrance alleles. FXN |
Friedreich ataxia | AR | Sensorispinal ataxia | — |
ITPR1 | SCA15 (OMIM 606658) | AD | Head tremor (not seen in SCA10) KCNC3 |
SCA13 | AD | Seizures may accompany relatively "pure" cerebellar ataxia.; Identified primarily in persons of Filipino French ancestry | — |
PPP2R2B | SCA12 (OMIM 604326) | AD | Head tremor (not seen in SCA10) PRKCG |
SCA14 | AD | Seizures may accompany relatively "pure" cerebellar ataxia.; Identified primarily in persons of European Japanese ancestry (most persons w/SCA10 are of Latin American/ Amerindian ancestry) TBP | — |
SCA17 | AD | Seizures AD = autosomal dominant; AR = autosomal recessive; DRPLA = dentatorubral-pallidoluysian atrophy; FXTAS = fragile X-associated tremor/ataxia syndrome; MOI = mode of inheritance; SCA = spinocerebellar ataxia; XL = X-linked SCA4. | — |
Source: GeneReviews — "Spinocerebellar Ataxia Type 10"
System/Concern | Evaluation | Comment |
|---|---|---|
Neurologic | Brain MRI examination | The extent of cerebellar atrophy on serial MRI studies may be useful for documenting progression of disease. EEG |
Other | Consultation w/clinical geneticist /or genetic counselor | Treatment of Manifestations Table 4. |
Treatment of Manifestations in Individuals with SCA10 Manifestation/Concern | Treatment | Considerations/Other |
Seizures | Conventional anticonvulsants (e.g., levetiracetam, phenytoin, carbamazepine, valproic acid) achieve reasonable control. | Uncontrolled seizures may lead to potentially fatal status epilepticus.; Occasional breakthrough seizures may occur. Ataxia |
Dysphagia | Percutaneous placement of gastrostomy tube for severe dysphagia | For prevention of aspiration Vitamin supplementation |
Upper-limb coordination issues | Weighted eating utensils dressing hooks | To maintain sense of independence |
Anxiety | Mild tranquilizers | May improve motor coordination Surveillance Table 5. |
Recommended Surveillance for Individuals with SCA10 System/Concern | Evaluation | Frequency |
Neurologic | Clinical evaluation w/neurologist | Every 4-6 mos to identify early signs of potential complications to adjust anticonvulsant treatments Video esophagrams can identify consistency of food least likely to trigger aspiration. |
Source: GeneReviews — "Spinocerebellar Ataxia Type 10"
Alcohol and drugs known to adversely affect cerebellar functions should be avoided. Falls should be avoided because resulting injuries may greatly compromise motor function and the ability to perform activities of daily living. Any activities that are potentially dangerous to individuals with ataxia or epilepsy should be avoided, depending on the severity of the manifestations.
Source: GeneReviews — "Spinocerebellar Ataxia Type 10"
Clinical trials of troriluzol (BHV-4157), a prodrug of riluzole, have included individuals with SCA10. Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "Spinocerebellar Ataxia Type 10"
1 trial found
Source: GeneReviews — "Spinocerebellar Ataxia Type 10"
Laboratory research | 10 | 30% |
Research summaries | 6 | 18% |
Disease patterns and progression | 4 | 12% |
Clinical study results | 2 | 6% |
New treatment approaches | 1 | 3% |
Gagrani M (2026). [PMID: 42220056](https://pubmed.ncbi.nlm.nih.gov/42220056/). *Ophthalmic Genet*. [Case Report / Case Series]
Morikawa-Yujiri Y (2026). [PMID: 42173623](https://pubmed.ncbi.nlm.nih.gov/42173623/). *J Pharmacol Sci*. [Basic Science / Preclinical]
Padron-Rivera G (2026). [PMID: 41653401](https://pubmed.ncbi.nlm.nih.gov/41653401/). *Brain Imaging Behav*. [Basic Science / Preclinical]
Chen LW (2026). [PMID: 42183960](https://pubmed.ncbi.nlm.nih.gov/42183960/). *Cerebellum*. [Basic Science / Preclinical]
Kirthana SH (2026). [PMID: 42132968](https://pubmed.ncbi.nlm.nih.gov/42132968/). *Cerebellum*. [Case Report / Case Series]
Huang HK (2026). [PMID: 41822190](https://pubmed.ncbi.nlm.nih.gov/41822190/). *Exp Ther Med*. [Case Report / Case Series]
Hines TJ (2026). [PMID: 41889878](https://pubmed.ncbi.nlm.nih.gov/41889878/). *bioRxiv*. [Basic Science / Preclinical]
Viana CF (2025). [PMID: 40358860](https://pubmed.ncbi.nlm.nih.gov/40358860/). *Cerebellum*. [Case Report / Case Series]
Keller Sarmiento IJ (2025). [PMID: 40156335](https://pubmed.ncbi.nlm.nih.gov/40156335/). *Mov Disord*. [Case Report / Case Series]
Chen YK (2025). [PMID: 39508583](https://pubmed.ncbi.nlm.nih.gov/39508583/). *Mov Disord*. [Clinical Trial Publication]